Allison Bratzel
Stock Analyst at Piper Sandler
(4.91)
# 240
Out of 4,704 analysts
262
Total ratings
59.5%
Success rate
38.7%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Allison Bratzel
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BMRN BioMarin Pharmaceutical | Maintained: Buy | $88 → $90 | $66.53 | +35.28% | 9 | Sep 1, 2026 | |
| CDXS Codexis | Maintained: Buy | $9 → $8 | $1.46 | +447.95% | 12 | Aug 17, 2026 | |
| INCY Incyte | Maintained: Buy | $110 → $130 | $126.75 | +2.56% | 13 | Aug 17, 2026 | |
| IONS Ionis Pharmaceuticals | Maintained: Buy | $100 → $94 | $58.09 | +61.82% | 14 | Aug 17, 2026 | |
| RIGL Rigel Pharmaceuticals | Maintained: Hold | $40 → $49 | $48.67 | +0.68% | 10 | Aug 17, 2026 | |
| TVTX Travere Therapeutics | Maintained: Buy | $49 → $68 | $65.28 | +4.17% | 21 | Aug 17, 2026 | |
| RARE Ultragenyx Pharmaceutical | Maintained: Buy | $68 | $15.30 | +344.44% | 7 | Aug 17, 2026 | |
| AKBA Akebia Therapeutics | Maintained: Buy | $4 | $0.9747 | +310.38% | 18 | Aug 17, 2026 | |
| ARDX Ardelyx | Maintained: Buy | $16 → $15 | $3.78 | +296.83% | 9 | Aug 17, 2026 | |
| ARGX argenx SE | Maintained: Buy | $1,075 → $1,215 | $1,033.15 | +17.60% | 34 | Aug 17, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $52 → $55 | $34.76 | +58.23% | 9 | Aug 17, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $30 | $13.89 | +115.98% | 7 | Aug 17, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $4 | $2.01 | +99.00% | 7 | Aug 17, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $1 | $0.6049 | +65.32% | 10 | Aug 17, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $12 | $4.82 | +148.96% | 6 | Aug 17, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $30 | $15.69 | +91.20% | 7 | Aug 17, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $14 | $15.04 | -6.91% | 10 | Aug 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $12 | $11.43 | +4.99% | 7 | Aug 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $165 → $175 | $114.79 | +52.45% | 13 | Jul 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $26 → $4 | $1.82 | +119.78% | 4 | May 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $42 → $56 | $28.65 | +95.46% | 5 | Mar 20, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $51 → $58 | $55.33 | +4.83% | 13 | Mar 4, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $3 → $0.5 | $0.0001 | +499,900.00% | 5 | Jan 23, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $22 | $34.93 | n/a | 6 | Jul 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | $8 → $20 | $10.25 | n/a | 6 | Mar 14, 2024 |
BioMarin Pharmaceutical
Sep 1, 2026
Maintained: Buy
Price Target: $88 → $90
Current: $66.53
Upside: +35.28%
Codexis
Aug 17, 2026
Maintained: Buy
Price Target: $9 → $8
Current: $1.46
Upside: +447.95%
Incyte
Aug 17, 2026
Maintained: Buy
Price Target: $110 → $130
Current: $126.75
Upside: +2.56%
Ionis Pharmaceuticals
Aug 17, 2026
Maintained: Buy
Price Target: $100 → $94
Current: $58.09
Upside: +61.82%
Rigel Pharmaceuticals
Aug 17, 2026
Maintained: Hold
Price Target: $40 → $49
Current: $48.67
Upside: +0.68%
Travere Therapeutics
Aug 17, 2026
Maintained: Buy
Price Target: $49 → $68
Current: $65.28
Upside: +4.17%
Ultragenyx Pharmaceutical
Aug 17, 2026
Maintained: Buy
Price Target: $68
Current: $15.30
Upside: +344.44%
Akebia Therapeutics
Aug 17, 2026
Maintained: Buy
Price Target: $4
Current: $0.9747
Upside: +310.38%
Ardelyx
Aug 17, 2026
Maintained: Buy
Price Target: $16 → $15
Current: $3.78
Upside: +296.83%
argenx SE
Aug 17, 2026
Maintained: Buy
Price Target: $1,075 → $1,215
Current: $1,033.15
Upside: +17.60%
Aug 17, 2026
Maintained: Buy
Price Target: $52 → $55
Current: $34.76
Upside: +58.23%
Aug 17, 2026
Maintained: Buy
Price Target: $30
Current: $13.89
Upside: +115.98%
Aug 17, 2026
Maintained: Buy
Price Target: $4
Current: $2.01
Upside: +99.00%
Aug 17, 2026
Maintained: Hold
Price Target: $1
Current: $0.6049
Upside: +65.32%
Aug 17, 2026
Maintained: Buy
Price Target: $12
Current: $4.82
Upside: +148.96%
Aug 17, 2026
Maintained: Buy
Price Target: $30
Current: $15.69
Upside: +91.20%
Aug 7, 2026
Maintained: Buy
Price Target: $14
Current: $15.04
Upside: -6.91%
Aug 7, 2026
Maintained: Buy
Price Target: $12
Current: $11.43
Upside: +4.99%
Jul 9, 2026
Rated: Buy
Price Target: $165 → $175
Current: $114.79
Upside: +52.45%
May 8, 2026
Downgraded: Hold
Price Target: $26 → $4
Current: $1.82
Upside: +119.78%
Mar 20, 2026
Maintained: Buy
Price Target: $42 → $56
Current: $28.65
Upside: +95.46%
Mar 4, 2026
Maintained: Buy
Price Target: $51 → $58
Current: $55.33
Upside: +4.83%
Jan 23, 2026
Downgraded: Hold
Price Target: $3 → $0.5
Current: $0.0001
Upside: +499,900.00%
Jul 18, 2024
Maintained: Buy
Price Target: $22
Current: $34.93
Upside: n/a
Mar 14, 2024
Upgraded: Buy
Price Target: $8 → $20
Current: $10.25
Upside: n/a